alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Drug trials: efficacy and safety

902 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Glucagon-like peptide-1 receptor agonists and mental health: a narrative review of emerging benefits and risks

    ✓ Peer-reviewed alzhub usefulness score 63 out of 100. Journal of Yeungnam medical science 2025-09-29 Drug development

    Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for type 2 diabetes mellitus and obesity, are increasingly recognized for their significant impact on the central nervous system, leading to reports of both beneficial and adverse mental health effects.

  2. Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study

    ✓ Peer-reviewed alzhub usefulness score 63 out of 100. Annals of internal medicine 2024-08-27 Drug development

    Overall, 12 489 patients initiating SGLT2 inhibitor treatment (51.9% dapagliflozin and 48.1% empagliflozin) and 1075 patients initiating dulaglutide treatment were included.

  3. Metformin mitigates dementia risk among individuals with type 2 diabetes

    ✓ Peer-reviewed alzhub usefulness score 63 out of 100. Clinical diabetes and endocrinology 2024-05-10 Drug development

    This mini-narrative review explores the relationship between diabetes and dementia, focusing on the potential mitigating role of metformin in reducing cognitive decline among individuals with type 2 diabetes.

  4. Galantamine plasma concentration and cognitive response in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 63 out of 100. PeerJ 2019-05-02 Treatments

    The total sample consisted of 33 clinically diagnosed AD patients taking galantamine 8 mg/d for 6 months.

  5. Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. EClinicalMedicine 2024-06-20 Drug development

    The pooled trial included 88,381 participants who received prescriptions for GLP-1 agonists (n = 12,351), DPP-4 inhibitors (n = 43,850), or sulfonylureas (n = 32,216) at baseline and were followed for an average of 4.3 years.

  6. TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. BJPsych Open 2023-07-01 Treatments

    This study provides the first active comparator data on amyloid plaque clearance in patients with early symptomatic AD.

  7. Searching for atrial fibrillation: looking harder, looking longer, and in increasingly sophisticated ways. An EHRA position paper

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. EP Europace 2022-08-24 Cognitive tests and assessment

    Atrial fibrillation (AF) is the most common clinical arrhythmia with substantial health and socioeconomic impact on healthcare.1 The number of people affected by this condition was estimated to be 33.5 million in 2010, with an increasing prevalence and incidence over the coming years.2 In 2017, there were 37.6 million [95% confidence interval (CI): 32.5–42.6 million] individuals with AF/atrial flutter globally.3 The estimated number of subjects with AF in 2030 in Europe will be 14–17 million, and the number of new cases of AF per year at 120 000–215 000.4 Atrial fibrillation is independently associated with increased mortality and morbidity from complications such as ischaemic stroke, dementia, and cognitive dysfunction.5 Oral anticoagulation can significantly reduce the risk of stroke, dementia, and death.6 As a part of a holistic or integrated approach to AF care, it is associated with improved outcomes7–9 and is advocated in guidelines.10,11 In many patients, AF can be asymptomatic, and the diagnosis is established after the appearance of a complication typically associated with AF, such as ischaemic stroke/systemic embolic or heart failure.

  8. Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Journal of Alzheimer's disease : JAD 2020-01-01 Treatments

    Crenezumab doses of ≤120 mg/kg intravenously q4w were well tolerated.

  9. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2016-03-02 Treatments

    Asymptomatic ARIA-E was detected in solanezumab-treated and placebo-treated AD patients.

  10. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Current Alzheimer research 2013-01-01 Drug development

    A lower incidence of dementia in bipolar patients treated with lithium has been described.

  11. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Journal of neurology, neurosurgery, and psychiatry 2008-10-17 Drug development

    In the general population, the use of statins, but not of non-statin cholesterol-lowering drugs, was associated with a lower risk of AD compared with never use of cholesterol-lowering drugs.

  12. Statin use and the risk of incident dementia: the Cardiovascular Health Study

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Archives of neurology 2005-07-01 Drug development

    In this cohort study, statin therapy was not associated with a decreased risk of dementia.

  13. A metaanalysis of controlled trials of neuroleptic treatment in dementia

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Journal of the American Geriatrics Society 1990-05-01 Clinical trials

    Prior qualitative literature reviews about the use of neuroleptics in dementia suggest that they are "modestly effective" in treating agitation and that no single neuroleptic is better than another.

  14. Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations

    ✓ Peer-reviewed alzhub usefulness score 61 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2025-11 Treatments

    Among 1005 amyloid-positive participants, 24.6% were eligible for lecanemab and 28.0% for donanemab (9.1% and 10.3% of the initial sample).

  15. Opposite causal effects of type 2 diabetes and metformin on Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 61 out of 100. The journal of prevention of Alzheimer's disease 2025-03-09 Drug development

    Our two-sample MR analysis indicated that T2D is not associated with the risk of AD (OR: 1.03, CI: 0.99-1.08, P = 0.128).

  16. Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study)

    ✓ Peer-reviewed alzhub usefulness score 61 out of 100. BMJ open 2022-02-21 Clinical trials

    Specifically, recent studies suggest that increased plasma concentrations of lipoprotein-Aβ compromise the brain microvasculature, resulting in extravasation and retention of the lipoprotein-Aβ moiety.

  17. EGb 761® Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer's Dementia-Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial

    ✓ Peer-reviewed alzhub usefulness score 61 out of 100. Healthcare (Basel, Switzerland) 2021-12-03 Clinical trials

    Following reports of bleeding upon Ginkgo intake, we assessed whether Ginkgo extract EGb 761® affects coagulation or platelet function or increases the risk of bleeding.

  18. The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer's Dementia: A Double-Blind Randomized Placebo-Controlled Trial

    ✓ Peer-reviewed alzhub usefulness score 61 out of 100. Psychiatry investigation 2021-03-10 Clinical trials

    There were no significant differences in age, sex, or education between AChEIs alone and combination groups.

  19. [Not Available]

    ✓ Peer-reviewed alzhub usefulness score 61 out of 100. Therapie 2015 Treatments

    Thirty-three patients were included: the revaluation of anti-dementia treatment led to 22 discontinuations and 11 continuations.

  20. Alzheimer's disease drug development pipeline: 2020

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia (New York, N. Y.) 2020-07-16 Drug development

    The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs.

  21. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. European journal of endocrinology 2019-11-01 Drug development

    Use of metformin, DPP4 inhibitors, GLP1 analogs and SGLT2 inhibitors was associated with lower risk of dementia in patients with diabetes.

  22. Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Frontiers in pharmacology 2025-05-30 Treatments

    Four signal calculation methods were used to assess potential adverse reaction signals of lecanemab and aducanumab.

  23. Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer's research & therapy 2025-01-08 Treatments

    Lecanemab may have a significant potential for AEs.

  24. Protocol of a Phase II Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. The journal of prevention of Alzheimer's disease 2023 Clinical trials

    The primary outcome is change in plasma p-tau181 concentration between baseline and following 180 days of treatment, which will be compared between the active and placebo group.

  25. Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. BMC medicine 2022-02-01 Treatments

    Overall, 1343 patients with MMSE scores were identified for internal validation and 285 [21.22%] took the drug recommended.

Other topics